<?xml version="1.0" encoding="UTF-8"?>
<p id="Par32">Decades have been spent to concoct universal influenza vaccines, and some solid progress has been achieved. Currently, several vaccine candidates are in early human clinical trials, with each vaccine candidate exploiting conserved regions of the virus to maximize breadth [reviewed in (Nachbagauer and Krammer, 
 <xref ref-type="bibr" rid="CR79">2017</xref>)]. Although some vaccine candidates such as those featured HA stalk have underwhelmed vaccine developers due to their poor effectiveness (Cohen 
 <xref ref-type="bibr" rid="CR15">2018</xref>), increasing numbers of new effective broad-protective immunogens (epitopes) have been discovered, providing attractive targets that should be explored in the development of novel universal influenza vaccines (Bajic 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR5">2019</xref>; Bangaru 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR6">2019</xref>; Stadlbauer 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR91">2019</xref>; Watanabe 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR106">2019</xref>).
</p>
